Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer.
about
Optimal management of muscle-invasive bladder cancer - a reviewA combined index to classify prognostic comorbidity in candidates for radical prostatectomyTrends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides.The Deyo-Charlson and Elixhauser-van Walraven Comorbidity Indices as predictors of mortality in critically ill patients.Impact of stage and comorbidities on five-year survival after radical cystectomy in Poland: single centre experience.Frailty as a marker of adverse outcomes in patients with bladder cancer undergoing radical cystectomyUsing Analytic Morphomics to Understand Short-Term Convalescence after Radical CystectomyExploration of ICD-9-CM coding of chronic disease within the Elixhauser Comorbidity Measure in patients with chronic heart failure.Comparative Effectiveness of Treatment Strategies for Bladder Cancer With Clinical Evidence of Regional Lymph Node Involvement.Impact of the ASA Physical Status Score on Adjuvant Chemotherapy Eligibility and Survival of Upper Tract Urothelial Carcinoma Patients: a Multicenter StudyRadical cystectomy and the implications of comorbidity.Diabetes and the hospitalized patient : A cluster analytic framework for characterizing the role of sex, race and comorbidity from 2006 to 2011.Pretreatment quality-of-life score is a better discriminator of oesophageal cancer survival than performance status.Age, American Society of Anesthesiologists physical status classification and Charlson score are independent predictors of 90-day mortality after radical cystectomy.Lee mortality index as comorbidity measure in patients undergoing radical cystectomy.The Author's Response: ASA Physical Status Classification in Surgical Oncology and the Importance of Improving Inter-Rater Reliability.Gender-specific survival following radical cystectomy for pT4 bladder cancer.The modified frailty index and 30-day adverse events in oncologic neurosurgery.Adapting the Elixhauser comorbidity index for cancer patients.Oncologic surveillance following radical cystectomy: an individualized risk-based approach.Sarcopenia as a comorbidity-independent predictor of survival following radical cystectomy for bladder cancer.Systematic Review of Comorbidity and Competing-risks Assessments for Bladder Cancer PatientsThe LACE Score as a Tool to Identify Radical Cystectomy Patients at Increased Risk of 90-Day Readmission and Mortality
P2860
Q26784038-CCC98C90-C9C5-4F76-985C-7DE1B0DE4D92Q35134283-9217D631-ED86-413C-A4F5-4F3144CE4194Q35748071-37D54E65-1949-4FAC-9A39-37E047C23AB1Q36038946-64B03312-D4ED-43D5-B123-6EEB4C7E605CQ36276796-D2FDC9DD-72B9-4684-B443-0907116501FDQ36923856-357409CD-0B5C-4C6D-B8AA-92CF04240E2AQ37053787-69148B3E-AFF8-4C3A-A4A1-451D2B9BC87BQ37231936-83CC8D2E-8C8B-462C-9EF7-C380E5611067Q37234834-62D15030-3151-41F8-99DF-5AD6D9255A22Q37570255-DADE3FF0-CE48-4BA3-B427-5CE397A2A076Q38176436-A5129061-CAF8-4511-AEC1-F0C1C90DC332Q38666240-FFCF02C6-BA66-40ED-BFE2-E7A0B187E048Q39506841-F3609139-AC83-4680-AFEA-F8CF06778DF2Q40219984-AA6BE1C3-304A-4266-8C8B-3AAB3D3DA958Q41446293-549CE811-F0CA-431F-A865-9383A9BF726EQ42341747-8E2FFBD4-E6B6-48E0-97E5-0D2791BAAE42Q45362887-63949AC9-DF91-43B8-B760-2E62CB60786FQ47594570-A71632E2-D852-43EA-9D2E-D9FC02C5E908Q48123202-33395AD9-3DD2-4DFE-A5E2-F5BCF5F5AB53Q48729142-893DD0D1-AB64-4B87-8493-0EDB2B8A10E2Q55343308-89DA50A8-13C4-4A67-B107-26AA982E8620Q57825314-97564190-03F5-4121-B4C4-5B735054988EQ58124380-1D06C699-D1D1-4998-B6A7-69EDAA30F13D
P2860
Comparative performance of comorbidity indices for estimating perioperative and 5-year all cause mortality following radical cystectomy for bladder cancer.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Comparative performance of com ...... cystectomy for bladder cancer.
@en
Comparative performance of com ...... cystectomy for bladder cancer.
@nl
type
label
Comparative performance of com ...... cystectomy for bladder cancer.
@en
Comparative performance of com ...... cystectomy for bladder cancer.
@nl
prefLabel
Comparative performance of com ...... cystectomy for bladder cancer.
@en
Comparative performance of com ...... cystectomy for bladder cancer.
@nl
P2093
P1476
Comparative performance of com ...... cystectomy for bladder cancer.
@en
P2093
Alonso Carrasco
Igor Frank
John C Cheville
Matthew K Tollefson
Prabin Thapa
R Houston Thompson
Simon P Kim
Stephen A Boorjian
P356
10.1016/J.JURO.2013.01.010
P407
P577
2013-01-09T00:00:00Z